{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T01:54:13Z","timestamp":1794966853666,"version":"4.9.1"},"reference-count":32,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,3,31]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>Single subcutaneous dosing of ACE910 has a linear PK profile, a half-life of 4 to 5 weeks, and FVIII-mimetic procoagulant activity in humans. ACE910 at doses up to 1 mg\/kg is well tolerated and has no notable adverse hypercoagulable effect in healthy Japanese and white adults.<\/jats:p>","DOI":"10.1182\/blood-2015-06-650226","type":"journal-article","created":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T22:23:59Z","timestamp":1449008639000},"page":"1633-1641","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":234,"title":["A first-in-human phase 1 study of ACE910, a novel factor VIII\u2013mimetic bispecific antibody, in healthy subjects"],"prefix":"10.1182","volume":"127","author":[{"given":"Naoki","family":"Uchida","sequence":"first","affiliation":[{"name":"Showa University Clinical Research Institute for Clinical Pharmacology and Therapeutics, Tokyo, Japan;"},{"name":"Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiko","family":"Sambe","sequence":"additional","affiliation":[{"name":"Showa University Clinical Research Institute for Clinical Pharmacology and Therapeutics, Tokyo, Japan;"},{"name":"Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Yoneyama","sequence":"additional","affiliation":[{"name":"Translational Clinical Research Division, Chugai Pharmaceutical Co. Ltd., Tokyo, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Fukazawa","sequence":"additional","affiliation":[{"name":"Translational Clinical Research Division, Chugai Pharmaceutical Co. Ltd., Tokyo, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiko","family":"Kawanishi","sequence":"additional","affiliation":[{"name":"Translational Clinical Research Division, Chugai Pharmaceutical Co. Ltd., Tokyo, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Showa University Clinical Research Institute for Clinical Pharmacology and Therapeutics, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midori","family":"Shima","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Nara Medical University, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019111902322159300_B1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia.","volume":"19","author":"Srivastava","year":"2013","journal-title":"Haemophilia"},{"issue":"5","key":"2019111902322159300_B2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1046\/j.1365-2796.1997.130135000.x","article-title":"Haemophilia prophylaxis in young patients \u2013 a long-term follow-up.","volume":"241","author":"L\u00f6fqvist","year":"1997","journal-title":"J Intern Med"},{"issue":"6","key":"2019111902322159300_B3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111902322159300_B4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2516.2006.01189.x","article-title":"Practice patterns in haemophilia A therapy \u2013 global progress towards optimal care.","volume":"12","author":"Geraghty","year":"2006","journal-title":"Haemophilia"},{"issue":"3","key":"2019111902322159300_B5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","article-title":"Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.","volume":"123","author":"Mahlangu","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111902322159300_B6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2516.2010.02370.x","article-title":"Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia.","volume":"17","author":"Collins","year":"2011","journal-title":"Haemophilia"},{"issue":"9","key":"2019111902322159300_B7","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1111\/j.1538-7836.2007.02663.x","article-title":"Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors.","volume":"5","author":"Konkle","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2019111902322159300_B8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/hae.12246","article-title":"Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors.","volume":"20","author":"Antunes","year":"2014","journal-title":"Haemophilia"},{"issue":"4","key":"2019111902322159300_B9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/01.mbc.0000169218.15926.34","article-title":"A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects.","volume":"16","author":"Fridberg","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"5","key":"2019111902322159300_B10","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2516.2007.01516.x","article-title":"A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation.","volume":"13","author":"Bysted","year":"2007","journal-title":"Haemophilia"},{"issue":"6","key":"2019111902322159300_B11","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/clpt.1994.80","article-title":"Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.","volume":"55","author":"Lindley","year":"1994","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"2019111902322159300_B12","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2516.2004.00925.x","article-title":"Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A.","volume":"10","author":"Villar","year":"2004","journal-title":"Haemophilia"},{"issue":"11","key":"2019111902322159300_B13","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1046\/j.1538-7836.2003.00450.x","article-title":"Monitoring the bioavailability of FEIBA with a thrombin generation assay.","volume":"1","author":"V\u00e1radi","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2019111902322159300_B14","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.tibtech.2013.08.007","article-title":"A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications.","volume":"31","author":"Byrne","year":"2013","journal-title":"Trends Biotechnol"},{"issue":"10","key":"2019111902322159300_B15","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"issue":"2","key":"2019111902322159300_B16","doi-asserted-by":"crossref","first-page":"e57479","DOI":"10.1371\/journal.pone.0057479","article-title":"Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity.","volume":"8","author":"Sampei","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"2019111902322159300_B17","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/jth.12474","article-title":"Anti-factor IXa\/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation.","volume":"12","author":"Muto","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"20","key":"2019111902322159300_B18","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2014-07-585737","article-title":"Anti-factor IXa\/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A.","volume":"124","author":"Muto","year":"2014","journal-title":"Blood"},{"key":"2019111902322159300_B19","unstructured":"European Medicines Agency\n          Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500002988.pdf. Accessed September 17, 2015"},{"key":"2019111902322159300_B20","unstructured":"US Food and Drug Administration\n          Guidance for industry (draft). Assay development for immunogenicity testing of therapeutic proteins. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM192750.pdf. Accessed on September 17, 2015"},{"issue":"13","key":"2019111902322159300_B21","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1182\/blood-2011-09-382846","article-title":"Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.","volume":"119","author":"Powell","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2019111902322159300_B22","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/jth.12161","article-title":"Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A.","volume":"11","author":"Tiede","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2019111902322159300_B23","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/jth.12506","article-title":"Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A.","volume":"12","author":"Coyle","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"suppl 4","key":"2019111902322159300_B24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/hae.12405","article-title":"Changing paradigm of prophylaxis with longer acting factor concentrates.","volume":"20","author":"Carcao","year":"2014","journal-title":"Haemophilia"},{"issue":"5","key":"2019111902322159300_B25","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jth.12864","article-title":"Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial.","volume":"13","author":"Chowdary","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2019111902322159300_B26","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40262-012-0027-4","article-title":"Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.","volume":"52","author":"Dostalek","year":"2013","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"2019111902322159300_B27","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/protein\/gzq009","article-title":"Reduced elimination of IgG antibodies by engineering the variable region.","volume":"23","author":"Igawa","year":"2010","journal-title":"Protein Eng Des Sel"},{"issue":"5","key":"2019111902322159300_B28","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10928-012-9260-6","article-title":"Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification.","volume":"39","author":"Peletier","year":"2012","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"2019111902322159300_B29","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/clpt.2008.170","article-title":"Monoclonal antibody pharmacokinetics and pharmacodynamics.","volume":"84","author":"Wang","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"suppl 3","key":"2019111902322159300_B30","first-page":"77","article-title":"In vitro characterization of ACE910, a humanized bispecific antibody to factors IXa and X [abstract].","volume":"20","author":"Soeda","year":"2014","journal-title":"Haemophilia"},{"issue":"4","key":"2019111902322159300_B31","doi-asserted-by":"crossref","first-page":"314","DOI":"10.4161\/self.1.4.13904","article-title":"Immunogenicity of protein therapeutics: the key causes, consequences and challenges.","volume":"1","author":"Baker","year":"2010","journal-title":"Self Nonself"},{"issue":"5","key":"2019111902322159300_B32","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/jcph.231","article-title":"A comprehensive review of the pharmacokinetics of approved therapeutic monoclonal antibodies in Japan: are Japanese phase I studies still needed?","volume":"54","author":"Chiba","year":"2014","journal-title":"J Clin Pharmacol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/127\/13\/1633\/1392227\/1633.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/127\/13\/1633\/1392227\/1633.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T02:35:26Z","timestamp":1574130926000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/127\/13\/1633\/34778\/A-firstinhuman-phase-1-study-of-ACE910-a-novel"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,31]]},"references-count":32,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2016,3,31]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2015-06-650226","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725980063.793544813","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,31]]}}}